Navigation Links
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
Date:3/30/2011

liver patients in Japan. We strongly believe that OCA has the potential to significantly add to the treatment options DSP can make available to these patients and are looking forward to working with Intercept to bring OCA to the market as an important new therapy for PBC and the first drug approved for NASH."

"This agreement is an important milestone for our OCA program and provides additional confirmation of our drug's potential," said Mark Pruzanski, MD, President and CEO of Intercept. "We are excited to be partnering in Asia with DSP, given its proven track record in the development and commercialization of drugs in the hepatology area. This collaboration with DSP will provide important development support as we advance OCA in parallel for PBC, NASH and possibly other indications."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist.  Intercept has previously announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC) and in type 2 diabetics with nonalcoholic fatty liver disease.  The clinical data and mechanism of action support OCA's potential as a novel, hepatoprotective agent in a broad range of chronic liver diseases.  

About Primary Biliary Cirrhosis (PBC)

PBC is the most common autoimmune chronic liver disease that primarily afflicts women over the age of 40. PBC causes substantial loss of intrahepatic bile ducts, resulting in impaired bile flow (cholestasis) and progressive fibrosis that leads eventually to cirrhosis. It is estimated that there are approximately 50,000 PBC patients in Japan and more than 400,000 in China.  Given inadequate treatment options, up to 50% of such patients worldwide continue to be at significant risk of progression to liver transplant or death.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
2. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
3. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
4. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
5. Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
6. Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011
7. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers
11. LodgeNet Healthcare Partners With American Society of Health-System Pharmacists to Improve Clinical Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... Review, 2015 market research report that provides an ... stage using data sourced from in-house databases, secondary ... syringes and needles market products pipeline spread across ... supported with 73 tables and 5 figures is ...
(Date:7/31/2015)... 2015  Xcelience, a contract development and manufacturing ... a structured cash investment in Powdersize, a ... micronization and powder size classification within the pharmaceutical ... while simultaneously adding a complete set of particle ... "As we continue to build ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... SYDNEY, May 23, 2011 Starpharma Holdings Limited (ASX: ... major phase 2 clinical study that demonstrated efficacy of ... Key Points: VivaGel(R) ... BV VivaGel(R) expected to avoid many shortcomings of ...
... Mass., May 20, 2011 Philips ... Philips FilterLine H Set and VitaLine H Set ... November 2010 through March 2011.ProductProduct DescriptionProduct Lot CodesM1923A ... M8330M10M8386N10M8411P10M8451P10M8477A11M8514A11M8572B11989803159581 , Philips Vitaline H Set Infant/Neo ...
Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines 2
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... in adults, revs up calorie-burning, experts say , , WEDNESDAY, April ... -- the brown fat revolution, that is. , ... verified that adult humans do possess this "good," slimming form ... and rodents. , The tissue is metabolically active and the ...
... 8 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or ... intra-operative MR held at PLA 301 Hospital in Beijing ... USA, Germany, Taiwan and Hong Kong attended the inaugural ... neurosurgery. The conference was opened by Dir Chen Xiaohong, ...
... Michael Eskew Named New Chair of Audit CommitteeINDIANAPOLIS, April 8 ... (NYSE: LLY ) today announced that J. Michael ... 2009. Mr. Cook, the retired chairman and chief executive officer ... the Lilly board since 2005. Mr. Cook has been a ...
... Serve Health Professionals, Instructors and Counselors , ... Today the American Psychological Association (APA) notified Humanitas, ... stringent criteria to offer continuing education credit hours ... programs. Humanitas offers a variety of educational ...
... Researchers and Updates on Key Discoveries, Plus Panel ... 8 Internationally renowned physician-scientists will discuss the ... plus important recent discoveries in translational cancer research, ... Research Foundation Clinical Investigator Symposium.The April ...
... 8 ORLANDO, Fla., April 8 James ... opening of his new dental practice, DellagioDentist.com, ... Orlando. This new dental practice, located at ... 8.(Photo: http://www.newscom.com/cgi-bin/prnh/20090408/CG96485 )Dr. Trantham and ...
Cached Medicine News:Health News:A Fat That May Keep You Thin 2Health News:A Fat That May Keep You Thin 3Health News:Neurosurgeons from around the world gather at PLA 301 Hospital in China 2Health News:J. Michael Cook to Retire from Lilly Board of Directors 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4Health News:New Family Dental Practice Opens in Orlando 2
The Nervous System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the nervous system....
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
Medicine Products: